Is Expanded GLP-1 Coverage Through Caremark Altering The Investment Case For CVS Health (CVS)?

Simply Wall St.06-02

In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640118089?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610","is_english":true,"pubTime":"2026-06-02 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640118089","market":"sg","top_or_hot":-1,"title":"Is Expanded GLP-1 Coverage Through Caremark Altering The Investment Case For CVS Health (CVS)?","media":"Simply Wall St.","content":"<div>\n<p>In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/is-expanded-glp-1-coverage-through-caremark-altering-the-inv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Expanded GLP-1 Coverage Through Caremark Altering The Investment Case For CVS Health (CVS)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Expanded GLP-1 Coverage Through Caremark Altering The Investment Case For CVS Health (CVS)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-02 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/is-expanded-glp-1-coverage-through-caremark-altering-the-inv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/is-expanded-glp-1-coverage-through-caremark-altering-the-inv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/is-expanded-glp-1-coverage-through-caremark-altering-the-inv","article_id":"2640118089","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/is-expanded-glp-1-coverage-through-caremark-altering-the-inv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640118089","pubTimestamp":1780388672,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the new-to-market block on the oral GLP-1 Foundayo (orforglipron) for plans that approve coverage.\nBy broadening access to GLP-1 weight management drugs while emphasizing affordability for plan sponsors, CVS Health is reinforcing its role as a pharmacy benefits manager focused on cost control and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","AIPO":"Defiance AI and Power Infrastructure ETF","BK4581":"高盛持仓","BK4144":"石油与天然气的储存和运输","BK4543":"AI","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4590":"PTP","BK4585":"ETF&股票定投概念","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4587":"ChatGPT概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4528":"SaaS概念","GLP":"Global Partners Lp","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","AGIX":"通用人工智能 ETF-AGIX","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","AI":"C3.ai, Inc.","BK4504":"桥水持仓","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","CVS":"西维斯健康","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4550":"红杉资本持仓","BK4588":"碎股","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","CVS.AU":"Cervantes Corp Ltd","BK4551":"寇图资本持仓","BK4196":"保健护理服务","BK4023":"应用软件"},"translate_title":"通过Caremark扩大GLP-1覆盖范围是否会改变CVS Health(CVS)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIYY":0.6,"AGIX":0.72,"CHAT":0.72,"GLP":1.5,"ARTY":0.72,"AIPO":0.82,"CVS.AU":1.5,"CVS":1.5,"AI":0.72},"content_text":"In late May 2026, CVS Health announced past updates to its CVS Caremark commercial formularies, reintroducing Zepbound (tirzepatide) as a preferred GLP-1 option from October 1, 2026, and lifting the new-to-market block on the oral GLP-1 Foundayo (orforglipron) for plans that approve coverage. By broadening access to GLP-1 weight management drugs while emphasizing affordability for plan sponsors, CVS Health is reinforcing its role as a pharmacy benefits manager focused on cost control and clinically guided access to high-demand therapies. We’ll now examine how this expansion of GLP-1 coverage through CVS Caremark could reshape CVS Health’s broader investment narrative and long-term positioning. Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementCVS Health Investment Narrative RecapTo own CVS Health, you have to believe in its integrated model across insurance, pharmacy benefits and retail care, and its ability to protect margins despite reimbursement and medical cost pressures. The Caremark decision to broaden GLP-1 access looks directionally supportive for its pharmacy benefits narrative, but the near term earnings story still appears most exposed to elevated medical costs and reimbursement pressure, so the news does not materially change the key catalyst or biggest risk right now. Among recent announcements, CVS Health’s plan to expand biosimilar use across high cost specialty drugs from July 2026 feels especially relevant, as it complements the GLP-1 moves by underlining a consistent focus on formulary management and affordability. Together, these updates sit at the heart of what investors are watching most closely: whether Caremark can keep controlling drug spend for plan sponsors while supporting CVS Health’s margin resilience. Yet, for investors, the real concern may be how rising medical costs and reimbursement pressure could ultimately affect... Read the full narrative on CVS Health (it's free!)CVS Health's narrative projects $452.9 billion revenue and $10.6 billion earnings by 2029.Uncover how CVS Health's forecasts yield a $101.58 fair value, a 12% upside to its current price.Exploring Other PerspectivesCVS 1-Year Stock Price Chart Five members of the Simply Wall St Community currently see CVS Health’s fair value between about US$101.6 and US$302.6, reflecting very different expectations. As you weigh those views, remember that persistent reimbursement pressure and elevated medical costs could be just as important to the company’s future as any individual growth initiative.Explore 5 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your CVS Health research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.Seeking Other Investments?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Uncover the next big thing with 24 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640118089","isCrawlerRequest":true}